Yufeng Shang

Yufeng Shang

Auto-generated profile, based on publicly available information

Yufeng Shang

Department of Hematology Zhongnan Hospital of Wuhan University Wuhan China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2021 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
YSY. F. Shang
Y. F. Shang
TLT. Liu
T. Liu
JYJ. N. Yu
J. N. Yu
XXX. R. Xu
X. R. Xu
KZK. R. Zahid
K. R. Zahid
FZFuling Zhou
Fuling Zhou
Objectives: To understand the sequelae of COVID‐19.Methods: We followed up 1174 patients with severe coronavirus disease 2019 (COVID‐19)who were recovered and discharged for 6 months.Results: There were 175 cases with clear IgG results 6 months after discharge, of which 82 (46.9%) were IgG (+) and 16 (9.1%) were IgG (dim+). Four hundred and forty‐one participants (55.4%) had some kind of sequelae. The most common symptoms were fatigue (25.3%), sleep disorder (23.2%) and shortness of breath (20.4%). In those who had sequelae, 262 (59.4%) had more than one symptom. Critical cases were more likely to have cough (20.5% vs 11.6%, p = 0.023) and hypomnesis (15.1% vs 8.0%, p = 0.041) than severe cases. Furthermore, univariate and multivariate logistic regression analyses revealed that women are more likely to have multiple symptoms (p = 0.002), fatigue (p = 0.009) and sleep disorder (p = 0.008), whereas critical illness was found as independent risk factor for hypomnesis (p = 0.045).Conclusion: Our study demonstrated the duration of antibody and sequelae of COVID‐19 and compared the differences amongst different populations.

11 November 2020 in Virulence
Verified
Journal Article
Open access
YYYalan Yu
Yalan Yu
TLTao Liu
Tao Liu
LSLiang Shao
Liang Shao
XLXinyi Li
Xinyi Li
CHColin K. He
Colin K. He
FZFuling Zhou
Fuling Zhou
A pandemic designated as Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading worldwide. Up to date, there is no efficient biomarker for the timely prediction of the disease progression in patients. To analyze the inflammatory profiles of COVID-19 patients and demonstrate their implications for the illness progression of COVID-19. Retrospective analysis of 3,265 confirmed COVID-19 cases hospitalized between 10 January 2020, and 26 March 2020 in three medical centers in Wuhan, China. Patients were diagnosed as COVID-19 and hospitalized in Leishenshan Hospital, Zhongnan Hospital of Wuhan University and The Seventh Hospital of Wuhan, China. Univariable and multivariable logistic regression models were used to determine the possible risk factors for disease progression. Moreover, cutoff values, the sensitivity and specificity of inflammatory parameters for disease progression were determined by MedCalc Version 19.2.0. Age (95%CI, 1.017 to 1.048; P < 0.001), serum amyloid A protein (SAA) (95%CI, 1.216 to 1.396; P < 0.001) and erythrocyte sedimentation rate (ESR) (95%CI, 1.006 to 1.045; P < 0.001) were likely the risk factors for the disease progression. The Area under the curve (AUC) of SAA for the progression of COVID-19 was 0.923, with the best predictive cutoff value of SAA of 12.4 mg/L, with a sensitivity of 83.9% and a specificity of 97.67%. SAA-containing parameters are novel promising ones for predicting disease progression in COVID-19.
1

31 July 2020 in Journal of Medical Virology
Verified
Journal Article
Open access
PDF file
YSYufeng Shang
Yufeng Shang
TLTao Liu
Tao Liu
JLJingfeng Li
Jingfeng Li
XWXinghuan Wang
Xinghuan Wang
FZFuling Zhou
Fuling Zhou
Coronavirus disease in 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is pandemic worldwide. SARS‐CoV‐2 IgM/IgG tests have been developed around the world for diagnosis and management of COVID‐19 patients, and sero‐epidemiological surveillance1.

3 December 2021 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
YSYufeng Shang
Yufeng Shang
YJYanxia Jin
Yanxia Jin
HLHailing Liu
Hailing Liu
LDLu Ding
Lu Ding
XTXiqin Tong
Xiqin Tong
FZFuling Zhou
Fuling Zhou

28 November 2018 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
WXWeili Xue
Weili Xue
WLWei-Ming Li
Wei-Ming Li
YSYufeng Shang
Yufeng Shang
YZYanjie Zhang
Yanjie Zhang
XLXuan Lan
Xuan Lan
MZMingzhi Zhang
Mingzhi Zhang
Novel nude mice model of human NK/T cell lymphoma were established by subcutaneously injecting two NK/T cell lymphoma cell lines into the right axillary region of mice and successful passages were completed by injecting cell suspension which was obtained through a 70‐μm cell strainer. These mice models and corresponding cell clones have been successfully developed for more than 8 generations. The survival rates of both resuscitation and transplantation in NKYS and YT models were 90% and 70% correspondingly. Pathologically, the tumour cells in all passages of the lymphoma‐bearing mice and cell lines obtained from tumours were parallel to initial cell lines. Immunologically, the tumour cells expressed the characteristics of the primary and essential NK/T lymphomas. The novel mice models maintained the essential features of human NK/T cell lymphoma, and they would be ideal tools in vivo for further research of human NK/T cell lymphoma.

15 April 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YSYufeng Shang
Yufeng Shang
TLTao Liu
Tao Liu
JLJingfeng Li
Jingfeng Li
NKNatasha Mupeta Kaweme
Natasha Mupeta Kaweme
XWXinghuan Wang
Xinghuan Wang
FZFuling Zhou
Fuling Zhou
The coronavirus disease 2019 (COVID-19) is widely spread and remains a global pandemic. Limited evidence on the systematic evaluation of the impact of treatment regimens on antibody responses exists. Our study aimed to analyze the role of antibody response on prognosis and determine factors influencing the IgG antibodies’ seroconversion. A total of 1,111 patients with mild to moderate COVID-19 symptoms admitted to Leishenshan Hospital in Wuhan were retrospectively analyzed. A serologic SARS-CoV-2 IgM/IgG antibody test was performed on all the patients 21 days after the onset of symptoms. Patient clinical characteristics were compared. In the study, 42 patients progressed to critical illness, with 6 mortalities reported while 1,069 patients reported mild to moderate disease. Advanced age (P = 0.028), gasping (P < 0.001), dyspnea (P = 0.024), and IgG negativity (P = 0.006) were associated with progression to critical illness. The mortality rate in critically ill patients with IgG antibody was 6.45% (95% CI 1.12–22.84%) and 36.36% (95% CI 12.36–68.38%) in patients with no IgG antibody (P = 0.003). Symptomatic patients were more likely to develop IgG antibody responses than asymptomatic patients. Using univariable analysis, fever (P < 0.001), gasping (P = 0.048), cancer (P < 0.001), cephalosporin (P = 0.015), and chloroquine/hydroxychloroquine (P = 0.021) were associated with IgG response. In the multivariable analysis, fever, cancer, cephalosporins, and chloroquine/hydroxychloroquine correlated independently with IgG response. We determined that the absence of SARS-CoV-2 antibody IgG in the convalescent stage had a specific predictive role in critical illness progression. Importantly, risk factors affecting seropositivity were identified, and the effect of antimalarial drugs on antibody response was determined.